<DOC>
	<DOCNO>NCT00097188</DOCNO>
	<brief_summary>This Phase II , randomize , double-blind , parallel group , placebo control , multicenter study evaluate safety efficacy Rituximab adult RRMS .</brief_summary>
	<brief_title>A Study Evaluate Rituximab Adults With Relapsing Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Ability willingness provide write informed consent comply schedule protocol assessment Age 1855 year , inclusive Diagnosis relapsing MS , define McDonald Criteria 14 History least one relapse subject 's medical record 1 year prior randomization EDSS screen 0 5.0 point , inclusive For subject reproductive potential ( male female ) , ability willingness use reliable mean contraception ( e.g. , hormonal contraceptive , patch , vaginal ring , intrauterine device , physical barrier ) study , include safety followup period , 1 year last dose study drug , even discontinue early study Pregnancy lactation Incompatibility MRI Lack peripheral venous access History severe , allergic , anaphylactic reaction humanize murine monoclonal antibody Known active bacterial , viral , fungal , mycobacterial infection , infection ( include atypical mycobacterial disease , exclude fungal infection nail bed recurrent herpes infection ) , major episode infection require hospitalization treatment IV antibiotic within 30 day prior screen oral antibiotic within 14 day prior screen History presence recurrent chronic infection ( e.g. , hepatitis B C , HIV , syphilis ) History cancer , include solid tumor hematologic malignancy ( except fully resolve resect cutaneous basal cell squamous cell carcinoma skin ) History alcohol drug abuse within 6 month prior screen History currently active primary secondary immunodeficiency Presence significant , uncontrolled disease cardiovascular , pulmonary , renal , hepatic , endocrine , gastrointestinal system Diagnosis secondary progressive , primary progressive , progressive relapse MS History presence vascular disease potentially affect brain spinal cord ( e.g. , stroke , transient ischemic attack , severe carotid stenosis , aortic aneurysm , intracranial aneurysm , hemorrhage , arteriovenous malformation ) History presence myelopathy due spinal cord compression disk vertebral disease History severe , clinically significant CNS trauma ( e.g. , cerebral contusion , spinal cord compression ) History intracranial intraspinal tumor ( e.g. , meningioma , glioma ) History presence potential metabolic cause encephalopathy myelopathy ( e.g. , untreated vitamin B12 deficiency , untreated thyroid deficiency ) History presence infectious cause encephalopathy myelopathy ( e.g. , syphilis , Lyme disease , human Tcell lymphotropic virus type 1 [ HTLV1 ] , herpes zoster myelopathy ) Neuromyelitis optica History presence systemic autoimmune disorder potentially cause progressive neurologic disease ( e.g. , lupus , antiphospholipid antibody syndrome , Sjogrenï¿½s syndrome , Behcet disease ) History presence sarcoidosis Relapse within 30 day prior randomization Previous treatment rituximab ( MabThera ( R ) /Rituxan ( R ) ) Treatment investigational agent within 90 day randomization five halflives investigational drug ( whichever longer ) Receipt live vaccine within 30 day prior randomization Previous treatment lymphocytedepleting therapy ( e.g. , Campath ( R ) , antiCD4 , cladribine , total body irradiation , bone marrow transplantation ) Treatment cyclophosphamide mitoxantrone within 12 month randomization Systemic corticosteroid therapy within 30 day randomization Treatment IFNBeta ; Copaxone ( R ) within 60 day randomization Treatment IVIG within 60 day randomization Plasmapheresis within 60 day randomization Treatment nonlymphocyte deplete immunosuppressive therapy ( e.g. , azathioprine , mycophenolate mofetil , cyclosporine ) within 90 day prior randomization Statins hormone replacement therapy start within 30 day randomization Positive pregnancy test Bcell count &lt; 1.1 % ( report percent CD19 ) Vitamin B12 low limit normal abnormal methylmalonic acid level Positive rapid plasma reagin Serum creatinine &gt; 1.4 mg/dL woman &gt; 1.6 mg/dL men Aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) &gt; 2.5 x upper limit normal Platelet count &lt; 100,000/mL Hemoglobin &lt; 8.5 g/dL Neutrophils &lt; 1.5 x 10^3/mL Serum IgG level 5.65 mg/mL serum IgM level 0.55 mg/mL Findings brain MRI scan consistent clinically significant condition MS Electrocardiogram ( ECG ) show significant abnormality treat investigator determines may jeopardize subject 's health ( i.e. , acute ischemia , leave bundle branch , bifascicular block )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Relapsing remit multiple sclerosis</keyword>
</DOC>